Tesamorelin: A GHRH Analogue Explained
One modification — a hexenoyl group on the N-terminus — solves the problem that ends native GHRH's activity in minutes. Everything else follows from it.
Tesamorelin is a 44-residue analogue of human growth hormone-releasing hormone, and it is one of the few research peptides whose modification can be stated in a single sentence: a trans-3-hexenoyl group attached to the N-terminus of GHRH(1–44). Everything interesting about it follows from that one change.
Why the N-terminus was modified
Native GHRH is degraded rapidly in circulation, and the primary route is dipeptidyl peptidase-4, which cleaves the first two residues from the N-terminus. Once those are gone the peptide no longer activates its receptor — the N-terminal region is essential for binding.
Attaching a hexenoyl group to the N-terminal tyrosine sterically obstructs the site DPP-4 must reach. The peptide keeps the sequence that binds the receptor and loses the vulnerability that ended its activity in minutes.
This is the same design logic seen elsewhere in the class, solved differently: CJC-1295 substitutes residues to block cleavage; semaglutide uses α-aminoisobutyric acid at the DPP-4 site. Three approaches to one enzyme.
Position in the GHRH literature
Tesamorelin acts at the GHRH receptor on pituitary somatotrophs, which distinguishes it from the GHRP class — ipamorelin, GHRP-2, hexarelin — that act at the ghrelin receptor GHS-R1a. The two classes are studied together precisely because they are separate pathways converging on the same output.
It is also one of the few compounds in the research-peptide catalog with a substantial clinical literature behind it, having been developed and studied as a pharmaceutical for HIV-associated lipodystrophy. That gives it an unusually well-characterised pharmacokinetic profile relative to most compounds in this space — the published data exist because a regulatory process required them.
What 44 residues means practically
Length is the dominant analytical fact. At 44 residues:
- Synthesis is demanding. Each coupling step is slightly imperfect, and those imperfections compound. Even at 99.5 per cent per step, a 44-mer yields under 80 per cent full-length chain before purification.
- Deletion sequences are the main impurity class — chains missing a single residue, structurally close to the product and difficult to separate chromatographically.
- Mass confirmation matters more than on a short peptide. A single missing residue changes the mass by roughly 100–190 Da, which mass spectrometry detects unambiguously while HPLC may not resolve it.
- Price reflects the step count, not the milligrams. A 44-mer is not comparable on a per-mg basis to a pentapeptide.
Molecular weight is approximately 5136 g/mol, and the acylated N-terminus should be reflected in the observed mass — a certificate reporting the mass of unmodified GHRH(1–44) would indicate the wrong material.
Handling
Longer peptides have more surface area, more conformational freedom and more scope for aggregation than short ones, so the standard rules carry more weight rather than less. Equilibrate cold vials before opening. Direct solvent down the vial wall. Swirl, never shake. Refrigerate after reconstitution and avoid freeze–thaw cycling.
Our reconstitution guide and storage notes cover the procedure in detail.
Tesamorelin is supplied strictly for laboratory research. We do not provide dosing information and nothing here describes use in humans. Every batch is analysed by an independent laboratory for HPLC purity and mass-spectrometric identity, with batch-matched certificates available on request.
All products and information referenced are for in-vitro research and laboratory use only. Nothing here is medical advice, and no therapeutic claim is made or implied.